Literature DB >> 11176129

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

R T Poon1, I O Ng, C Lau, L X Zhu, W C Yu, C M Lo, S T Fan, J Wong.   

Abstract

OBJECTIVE: To evaluate the correlation between serum vascular endothelial growth factor (VEGF) level and the clinicopathologic features in patients with hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: VEGF is an important angiogenic factor regulating tumor angiogenesis. A high serum VEGF level has been shown to be associated with tumor progression and metastasis in several human cancers, but its significance in HCC is unclear. The correlation between serum VEGF level and tumor pathologic features in patients with HCC has not been studied before.
METHODS: Preoperative serum samples and tumor specimens were prospectively collected in 100 patients undergoing resection of HCC. Serum VEGF level was measured by enzyme-linked immunosorbent assay, and tumor VEGF expression was assessed by immunohistochemical study. Histopathologic examination was performed by a pathologist without prior knowledge of the serum VEGF level or tumor VEGF expression.
RESULTS: Preoperative serum VEGF levels ranged from 15 to 1,789 pg/mL (median 269). When serum VEGF levels were compared between groups categorized by different clinicopathologic variables, significant correlation was found between a high serum VEGF level and absence of tumor capsule, presence of intrahepatic metastasis, presence of microscopic venous invasion, and advanced stage. There was a positive correlation between the serum VEGF level and tumor expression of VEGF as well as platelet count. When the 75th percentile serum VEGF level (500 pg/mL) was used as a cutoff level, the frequency of venous invasion in patients with a high serum VEGF level was significantly greater compared with patients with a low serum VEGF level. By multivariate analysis, a serum VEGF level of more than 500 pg/mL and tumor size more than 5 cm were independent preoperative factors predictive of microscopic venous invasion. During a median follow-up of 11.6 months, 48% of patients with a serum VEGF level of more than 500 pg/mL and 27% of those with a serum VEGF level of 500 pg/mL or less developed postoperative recurrence.
CONCLUSIONS: These results show that a high preoperative serum VEGF level is a predictor of microscopic venous invasion in HCC, suggesting that the serum VEGF level may be useful as a biologic marker of tumor invasiveness and a prognostic factor in HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176129      PMCID: PMC1421205          DOI: 10.1097/00000658-200102000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  47 in total

Review 1.  Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction.

Authors:  J Folkman
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

2.  Lack of intrahepatic recurrence of hepatocellular carcinoma by temporary portal venous embolization with starch microspheres.

Authors:  T Matsumata; T Kanematsu; K Takenaka; K Sugimachi
Journal:  Surgery       Date:  1989-02       Impact factor: 3.982

3.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; E J Manseau; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

4.  Constitutive expression of the thrombopoietin gene in a human hepatoma cell line.

Authors:  M Hino; Y Nishizawa; S Tagawa; T Yamane; H Morii; N Tatsumi
Journal:  Biochem Biophys Res Commun       Date:  1995-12-14       Impact factor: 3.575

5.  Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.

Authors:  N Nagasue; M Uchida; Y Makino; Y Takemoto; A Yamanoi; T Hayashi; Y C Chang; H Kohno; T Nakamura; H Yukaya
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

6.  Hepatic resection versus transplantation for hepatocellular carcinoma.

Authors:  S Iwatsuki; T E Starzl; D G Sheahan; I Yokoyama; A J Demetris; S Todo; A G Tzakis; D H Van Thiel; B Carr; R Selby
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

7.  Preoperative chemoembolization of hepatocellular carcinoma: a comparative study.

Authors:  F Paye; P Jagot; V Vilgrain; O Farges; D Borie; J Belghiti
Journal:  Arch Surg       Date:  1998-07

8.  Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma.

Authors:  J N Vauthey; D Klimstra; D Franceschi; Y Tao; J Fortner; L Blumgart; M Brennan
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

9.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; A J Guidi; H F Dvorak; D R Senger; J L Connolly; S J Schnitt
Journal:  Hum Pathol       Date:  1995-01       Impact factor: 3.466

10.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

View more
  64 in total

Review 1.  Moving toward an understanding of the metastatic process in hepatocellular carcinoma.

Authors:  W M Korn
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Biomarkers and Personalized Sorafenib Therapy.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

3.  Accomplishments in 2007 in the management of hepatobiliary cancers.

Authors:  Anthony T C Chan; Yoji Kishi; Stephen L Chan; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2008-05

4.  Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma.

Authors:  Amr Mohamed; Avantika Chenna; Mohamed Abdelfatah; Jain Sanjay; M K Mohammad; Ibrahim Saber; John Kauh; Balsam Elhammali; Ahmed Kaseb
Journal:  J Gastrointest Cancer       Date:  2015-06

Review 5.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

Review 6.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.

Authors:  Xin Li; Gan-Sheng Feng; Chuan-Sheng Zheng; Chen-Kai Zhuo; Xi Liu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

10.  Expression of intercellular adhesion molecule-1 in the livers of rats treated with diethylnitrosamine.

Authors:  Shunichi Matsuoka; Hiroshi Matsumura; Yasuo Arakawa; Hitomi Nakamura; Kazushige Nirei; Hiroaki Yamagami; Masahiro Ogawa; Noriko Nakajima; Shunichi Amaki; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.